Skip to main content

Advertisement

PReS13-SPK-1587: New biologic targets for the future and basic science behind them

Article metrics

  • 812 Accesses

The treatment of paediatric rheumatic diseases has made great progress in the last decade. The introduction of the biologicals meant (after the introduction of MTX) the second therapeutic revolution. This together with many improvements in related areas has greatly improved the quality of life of patients with rheumatic diseases. At present however, despite the introduction of more biological agents directed at immune targets the progression has stalled. The next challenge will be to:

1) Better understand the immune pathogenesis underlying the heterogeneity of the disease.

2) Identify patients at risk at the onset of disease and stratify them according to risk factors.

3) Personalize treatment based on their risk profiling.

4) Develop strategies that are aimed not only at suppressing disease but also at maintaining disease remission after withdrawing immune suprresion.

Over the last years much progress has been made in all these area's. In this presentation we will discuss this progress, focusing on a better understanding of the mechanisms of immune tolerance, leading to new targets for intervention.

Disclosure of interest

B. Prakken Grant/Research Support from: Dutch Arthritis Foundation.

References

  1. 1.

    Zonneveld-Huijssoon E, et al: TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. Annals of the rheumatic diseases. 2012, 71 (10): 1706-1715. 10.1136/annrheumdis-2011-201131.

  2. 2.

    Wehrens E, et al: T cells out of control-impaired immune regulation in the inflamed joint. Nature reviews. Rheumatology. 2012, doi:10.1038/nrrheum.2012.149

  3. 3.

    Albani S, et al: Induction of immune tolerance in the treatment of rheumatoid arthritis. Nature reviews. Rheumatology. 2011, 7 (5): 272-281. 10.1038/nrrheum.2011.36.

  4. 4.

    Prakken B, et al: Juvenile idiopathic arthritis. 2011, Lancet, 377 (9783): 2138-2149.

Download references

Author information

Correspondence to B Prakken.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Cite this article

Prakken, B. PReS13-SPK-1587: New biologic targets for the future and basic science behind them. Pediatr Rheumatol 11, I17 (2013) doi:10.1186/1546-0096-11-S2-I17

Download citation

Keywords

  • Public Health
  • Arthritis
  • Basic Science
  • Rheumatic Disease
  • Biological Agent